Introduction {#sec1-1}
============

Primary open-angle glaucoma (POAG) is a progressive, chronic optic neuropathy in adults, and it is characterized by open anterior chamber angles, visual field abnormalities, and high intraocular pressure (IOP). Glaucoma, affecting at least 90 million people worldwide, is a leading cause of blindness, second only to cataract. It has been estimated that by 2010, almost 60.5 million people will have POAG worldwide, and by 2020, this number is expected to increase to 79.6 million, which will result blindness in 11.2 million people by 2020.\[[@ref1]\] Previous studies suggest that the genetic factors may play important roles in the pathogenesis of this disease.\[[@ref2][@ref3]\] Linkage analyses have established three POAG susceptibility genes: myocilin, optineurin, and WD repeat domain 36.\[[@ref4][@ref5][@ref6]\] Association studies using single nucleotide polymorphisms (SNPs) have substantially contributed to the study of glaucoma over the past few decades; however, the link between the genes and the development of the disease is not always clearly demonstrated.

Fatty acid-binding proteins (FABPs) are small intracellular polypeptides expressed in the absorptive simple columnar epithelial cells of the intestine (enterocytes).\[[@ref7]\] The *FABP2* gene encodes intestinal FABP protein, involved in fatty acid transfer and metabolism.\[[@ref8]\] The gene consists of 3382 nucleotides located in the chromosomal region 4q28--4q31, arranged in four exons containing −700 bp and three introns containing −2650 bp.\[[@ref7][@ref9]\] Earlier studies have shown that the Ala54Thr polymorphism of the *FABP2* gene can be commonly found in around 30% of the most populations and is significantly associated with insulin resistance,\[[@ref10]\] dyslipidemia, and obesity.\[[@ref11]\] Genome-wide association (GWA) studies have indicated that the fat mass and obesity-associated (*FTO*) gene has an important genetic effect on body mass index (BMI) and risk of obesity. Obesity has been postulated to exert an effect on IOP by causing excessive intraorbital adipose tissue, increased blood viscosity, increased episcleral venous pressure, and impairment of aqueous outflow facility. Previous studies have shown that overweight and obesity are independent risk factors for increase in IOP.\[[@ref12][@ref13][@ref14][@ref15]\] Raised IOP is an important risk factor for the progression to POAG. In cases of POAG as a matter of observation, it can be inferred that the individual ones to intermittently affect with obesity might be susceptible to such conditions. Hence, the present study was carried out to investigate the association of *FABP2* and *FTO* gene polymorphism with POAG cases and controls.

Materials and Methods {#sec1-2}
=====================

Patient\'s selection {#sec2-1}
--------------------

A total of 122 blood samples of POAG cases and 112 healthy controls were collected from the Department of ophthalmology of Era\'s Lucknow Medical College and Hospital, Lucknow. Data collection was done for each patient on clinical variables including age, alcohol consumption, BMI, height, weight, cigarette smoking, and family history. Each individual underwent a complete ophthalmological examination. Patients with POAG were defined by the presence of an open angle, pathological cupping of the optic disc, a glaucoma hemifield test (GHT) outside normal limits with reproducible visual field defects at the same location on two consecutive visits, and an IOP \>21 mmHg without antiglaucoma drugs. Cup-to-disc ratios were between 0.4 and 0.9. Patients with a history of eye surgery before the diagnosis of glaucoma, evidence of secondary glaucoma such as exfoliation, pigment dispersion or uveitis, and other causes were excluded from the study. Control group was nonsmokers and had neither diabetes nor any systemic illness. They had no family or personal history of glaucoma. They had clinical healthy appearing optic discs as demonstrated by indirect ophthalmoscope with a cup-to-disc ratio of 0.3 or lower and GHT within normal limits. Ethical Committee\'s clearances were obtained from the respective departments, earlier to the recruitment of individuals in this study.

DNA extraction {#sec2-2}
--------------

Five milliliters of peripheral blood was collected from all the individuals in 0.5M EDTA tubes. Genomic DNA was isolated from whole blood using the standard phenol-chloroform extraction method.\[[@ref16]\] The DNA concentration was determined by spectrophotometer and stored at −20°C.

Analysis of polymorphisms {#sec2-3}
-------------------------

### Fatty acid-binding protein 2 polymorphism {#sec3-1}

Polymerase chain reaction (PCR) was employed for genotyping of the *FABP2* gene polymorphism. Reactions were performed with 10 pmol of each primer:\[[@ref17]\] forward primers 5'-ACAGGTGTTAATATAGTGAAAAG-3' and reverse primer 5'-TACCCTGAGTTCAGTTCCGTC-3'. In the final volume of 20 μl containing 0.3 U of Taq DNA polymerase, 10 mmol/l Tris-HCl pH 8.3, 50 mmol/l of KCl, 1.5 mmol/l of MgCl~2~, and 100 mmol/l of dNTPs, PCR amplification was carried out under the conditions: 35 cycles for 1 min at 94°C, 1 min at 58°C, and 1 min at 72°C; the PCR products were analyzed on 2% agarose gel stained with ethidium bromide to certify the proper amplification. The amplified PCR products of 180 bp were digested with the addition of 2 U HhaI (New England Biolabs, Hitchin, UK), 10 mmol/l Tris-HCl pH 7.9, 50 mmol/l NaCl, 10 mmol/l MgCl~2~, and 1 mmol/l dithiothreitol. After incubation at 37°C for 2 h, digested samples were separated on 10% ethidium bromide-stained polyacrylamide gel electrophoresis and visualized by UVP BIOLMAGING gel doc system. PCR products having an intact HhaI site were cleaved into 99- and 81-bp fragments; the Ala54Thr substitution abolished the restriction site \[[Figure 1](#F1){ref-type="fig"}\].

![Polyacrylamide gel picture showing digested polymerase chain reaction products for fatty acid-binding protein 2 gene polymorphism. Lane 1: Undigested polymerase chain reaction product of fatty acid-binding protein 2 (180 bp), lane 5-7: TT genotype, lane 2 and 4: AT genotype, lane 3: 100 bp ladder](TJO-7-138-g001){#F1}

### Fat mass and obesity-associated polymorphism {#sec3-2}

The *FTO* SNP (rs9939609) was genotyped by PCR (MJ Mini Thermo Cycler BioRad, USA) and restriction fragment length polymorphism analysis. Genomic DNA (20 ng) was incubated in a 10-μl solution containing 1X NH4 buffer, 2.5 mmol/l magnesium, 200 μmol/l each dNTP, 20 pmol forward (5'-AACTGGCTCTTGAATGAAATAGGAT TCAGA-3') and reverse (5'-AGAGTAACAGAGA CTATCCAAGTG CAGTAC-3') oligonucleotide primers,\[[@ref18]\] and 0.5 U Taq DNA polymerase (Bioline Ltd., London, UK). The PCR mix was incubated at 94°C for 5 min followed by 20 cycles of 94°C for 45 s, 61°C for 45 s (dropping 0.5 C per cycle), and 72°C for 45 s. After this, the PCR mix was incubated for 15 cycles of 94°C for 45 s, 51°C for 45 s, and 72°C for 45 s, followed by the final incubation at 72°C for 10 min. The PCR products thus obtained were incubated at 37°C for 16 h with 2 U ScaI (New England Biolabs, Hitchin, UK). Upon running the final products on a 3% agarose gel, the T allele produced a 182-bp band and the A allele produced 154- and 28-bp bands \[[Figure 2](#F2){ref-type="fig"}\].

![Polyacrylamide gel picture showing digested polymerase chain reaction products for fat mass and obesity-associated gene polymorphism. Lane 2, 3, and 6 show AT genotype (182 and 154), lane 4 and 7 show TT genotype (182 bp), lane 5 shows 100 bp ladder, and lane 1 shows undigested polymerase chain reaction product of *FTO* (182 bp)](TJO-7-138-g002){#F2}

Statistical analysis {#sec2-4}
--------------------

All the figures are presented as means ± standard deviation. The genotyping data were compared between cases and controls using Chi-square test. Other variables were compared using Student\'s *t*-test for normally distributed variables. All statistical tests were performed using Statistical Package for the Social Sciences version 12 software (IBM, USA).

Results {#sec1-3}
=======

Our study included 122 POAG cases (65 were males and 57 were females) and 112 controls (59 were males and 53 were females). The mean ages were 49.88 ± 12.34 and 53.74 ± 11.87 years in POAG cases and control groups, respectively. Clinical and biochemical parameters of cases and controls are shown in [Table 1](#T1){ref-type="table"}. In our population, the mean red blood cell (RBC) lysate glutathione (GSH) levels were significantly lower in cases as compare to the controls (*P* \< 0.05). *FABP2* gene AA, AT, TT genotype frequencies were 12.90%, 62.40%, 24.80% in POAG cases and 20.60%, 64.70%, 14.70% in healthy controls, respectively. Odds ratio (OR) for AA was 0.569 (95% confidence interval \[CI\] 0.27--1.21, *P* = 0.141, χ^2^ = 2.17, power = 0.875), for AT 0.904 (95% CI 0.51--1.60, *P* = 0.73, χ^2^ = 0.12, power = 0.644), and for TT 1.908 (95% CI 0.94--3.88, *P* = 0.072, χ^2^ = 3.24, power = 0.925). The frequencies of A and T allele in POAG cases were 44.06% and 54.94% as compared to 52.94% and 47.06% in the controls. OR for A was 0.700 (95% CI 0.47--1.03, *P* = 0.074, χ^2^ = 3.21, power = 0.845) and for T 1.428 (95% CI 0.97--2.11, *P* = 0.074, χ^2^ = 3.21, power = 0.845). The *FTO* gene AA, AT, TT genotype frequencies were 2%, 79.20%, 18.80% in cases and 0%, 75.50%, 24.50% in healthy controls, respectively. OR for AA was not available (NA) (95% CI NA, *P* = 0.153, χ^2^ = 2.05, power = 0.958), for AT 1.237 (95% CI 0.64--2.39, *P* = 0.527, χ^2^ = 0.40, power = 0.843), and for TT 0.714 (95% CI 0.36--1.40, *P* = 0.324, χ^2^ = 0.97, power = 0.892). The frequencies of A and T allele in POAG cases were 41.58% and 58.42% as compared to 37.75% and 62.25% in the controls. OR for A was 1.174 (95% CI 0.79--1.75, *P* = 0.429, χ^2^ = 0.63, power = 0.844) and for T 0.852 (95% CI 0.57--1.27, *P* = 0.429, χ^2^ = 0.63, power = 0.844). The genotype, allele\'s frequencies of *FABP2*, *FTO* and statistical analysis among the cases and controls are also shown in [Table 2](#T2){ref-type="table"}. Genotype distribution for all investigated SNPs was in Hardy--Weinberg equilibrium in both cases and controls.

###### 

Clinical and biochemical profile of primary open-angle glaucoma cases and controls

  Parameters                   POAG cases (*n*=122)   Control (*n*=112)
  ---------------------------- ---------------------- -------------------
  Gender (male/female)         65/57                  59/53
  Age (years)                  49.88±12.34            53.74±11.87
  BMI                          23.61±4.71             21.24±3.93
  SBP (mm Hg)                  128.32±22.15           122.30±2019
  DBP (mm Hg)                  79.06±22.14            82.15±19.30
  RBS (mg/dl)                  113.97±24.22           124±61.47
  Hb (g%)                      14.10±4.11             14.45±1.65
  TLC (cell/cumm)              7183.83±1841.84        7571.70±1690.06
  Neutrophils (%)              66.43±8.49             65.35±6.73
  Lymphocytes (%)              27.78±8.24             28.70±6.73
  Eosinophils (%)              4.07±2.64              4.58±2.89
  Monocytes (%)                2.02±4.76              1.19±3.20
  Platelet count (lakh/cumm)   1.98±0.65              1.99±0.68

*n* = Number of participants. POAG = Primary open-angle glaucoma, BMI = Body mass index, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, RBS = Random blood sugar, Hb = Hemoglobin, TLC = Total lymphocyte count

###### 

Genotypes and alleles frequency of *FABP2* and *FTO* genes in primary open-angle glaucoma cases and controls

              Control (102)   POAG (101)   OR    95% CI   *χ*^2^   *P*         Bonferroni corrected *P*   Power           
  ----------- --------------- ------------ ----- -------- -------- ----------- -------------------------- ------- ------- -------
  *FABP2*                                                                                                                 
   Genotype                                                                                                               
    AA        23              20.60        16    12.90    0.569    0.27-1.21   2.17                       0.141   0.423   0.875
    AT        72              64.70        76    62.40    0.904    0.51-1.60   0.12                       0.73    1.000   0.644
    TT        17              14.70        30    24.80    1.908    0.94-3.88   3.24                       0.072   0.216   0.925
    Allele                                                                                                                
    A         119             52.94        108   44.06    0.700    0.47-1.03   3.21                       0.074   0.147   0.845
    T         105             47.06        136   55.94    1.428    0.97-2.11   3.21                       0.074   0.147   0.845
  *FTO*                                                                                                                   
   Genotype                                                                                                               
    AA        0               \-           2     2.00     NA       NA          2.05                       0.153   0.460   0.958
    AT        85              75.50        97    79.20    1.237    0.64-2.39   0.40                       0.527   1.000   0.843
    TT        27              24.50        23    18.80    0.714    0.36-1.40   0.97                       0.324   0.974   0.892
   Allele                                                                                                                 
    A         85              37.75        101   41.58    1.174    0.79-1.75   0.63                       0.429   0.858   0.844
    T         139             62.25        143   58.42    0.852    0.57-1.27   0.63                       0.429   0.858   0.844

OR = Odds ratio, CI = Confidence interval, NA = Not available, POAG = Primary open-angle glaucoma, FABP2 = Fatty acid-binding protein 2

Discussion {#sec1-4}
==========

Glaucoma is accurately defined as an optic neuropathy involving a characteristic atrophy of the optic nerve head. It is usually results from decreased outflow of aqueous fluid due to an acceleration and exaggeration of normal aging changes in the anterior chamber angle, iris, and ciliary body tissues of the eye. If it is untreated, the natural course is toward blindness or significant visual loss disability. We have observed that the mean RBC lysate GSH levels were significantly lower in cases as compare to the controls, similar finding were observed in the UK population where patients with glaucoma exhibit low levels of circulating GSH.\[[@ref19]\]

Fatty acid-binding protein 2 polymorphism {#sec2-5}
-----------------------------------------

*FABP2* gene is expressed only in the absorptive simple columnar epithelial cells of the small intestine.\[[@ref20]\] According to Hongmei *et al*., the evidence of decreased blood flow to the optic nerve is directly influenced by fatty acids, and further investigation result shows abnormal blood fatty acid composition in POAG patients compared to a healthy control. Indeed, the POAG patients studied had reduced total omega-3 long-chain polyunsaturated fatty acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) fatty acids.\[[@ref7]\] These findings may be significant as EPA and DHA could modulate impaired systemic microcirculation, ocular blood flow, and positively impact optic neuropathy, which are the main physiological changes associated with glaucoma.\[[@ref21]\] Numerous studies have assessed *FABP2* gene variants and their association with insulin resistance and type 2 diabetes mellitus.\[[@ref7]\] This is the first time we are reporting this gene polymorphism in POAG cases. We have observed that the frequency of *FABP2* AA, AT, TT genotype were 12.90%, 62.40%, 24.80% in POAG cases and 20.60%, 64.70%, 14.70% in healthy controls, respectively. In our study, we have found no significant association of *FABP2* gene polymorphism in North Indian POAG cases \[[Table 2](#T2){ref-type="table"}\].

Fat mass and obesity-associated polymorphism {#sec2-6}
--------------------------------------------

*FTO* gene is associated with an increased BMI, risk of myocardial infarction, and cardiovascular death. GWA studies first describe the link between genetic variation in *FTO* and obesity,\[[@ref22]\] and later, it was confirmed in different populations all over the world. Obesity is one of the major risk factors for several diseases such as type 2 diabetes, hypertension, stroke, osteoarthritis, and sleep apnea syndrome; some eye diseases such as glaucoma,\[[@ref23]\] cataract,\[[@ref24]\] diabetic retinopathy,\[[@ref25]\] and age-related macular degeneration were reported to have potential relation to obesity.\[[@ref26]\] In our study, we found that *FTO* gene AA, AT, TT genotype frequencies were 2%, 79.20%, 18.80% in cases and 0%, 75.50%, 24.50% in healthy controls, respectively. Frequencies of A and T allele in POAG cases were 41.58% and 58.42% as compared to 37.75% and 62.25% in the controls. Our results show no significant association between the AA, AT, TT genotype of *FABP2* and POAG (*P* = 0.153, 0.527, 0.324). Adequate data of *FTO* polymorphism and POAG were not available.

Conclusion {#sec1-5}
==========

We could not identify the possible association of *FABP2* and *FTO* gene polymorphism with POAG; however, further studies with larger sample size in different population are require to clarify the role of *FABP2* and *FTO* genes in susceptibility to POAG.

Financial support and sponsorship {#sec2-7}
---------------------------------

The authors have no funding to disclose.

Conflicts of interest {#sec2-8}
---------------------

There are no conflicts of interest.

We are thankful for the study that was supported by intramural grant from the Era\'s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
